研究文章
甲真菌病在银屑病患者指甲疾病:病原学的代理和免疫抑制治疗
|
| 药物 |
的患者数量,n(%) |
甲真菌病,n(%) |
没有甲真菌病,n(%) |
|
| Acitretin |
3 (7.89) |
1 (2.63) |
2 (5.26) |
| 甲氨蝶呤 |
14 (36.82) |
13 (34.19) |
1 (2.63) |
| Adalimumab |
4 (10.52) |
3 (7.89) |
1 (2.63) |
| 道, |
3 (7.89) |
1 (2.63) |
2 (5.26) |
| 英夫利昔单抗 |
1 (2.63) |
1 (2.63) |
0 |
| Secukinumab |
2 (2.63) |
0 |
2 (5.26) |
| Golimumab |
2 (2.63) |
0 |
2 (5.26) |
| 甲氨蝶呤+ adalimumab |
2 (2.63) |
1 (2.63) |
1 (2.63) |
| 甲氨蝶呤+道 |
2 (2.63) |
1 (2.63) |
1 (2.63) |
| 甲氨蝶呤+英夫利昔单抗 |
2 (2.63) |
0 |
2 (5.26) |
| 没有一个 |
3 (7.89) |
1 (2.63) |
2 (5.26) |
| 总 |
38 (100) |
22日(57.86) |
16 (42.08) |
|
|
